Previous close | 750.77 |
Open | 749.42 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1100 |
Day's range | 743.77 - 752.20 |
52-week range | 370.68 - 800.78 |
Volume | |
Avg. volume | 3,050,669 |
Market cap | 709.224B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 128.17 |
EPS (TTM) | 5.82 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | 5.20 (0.70%) |
Ex-dividend date | 14 Feb 2024 |
1y target est | 826.94 |
In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.